UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| 1 |
Apple
AAPL
|
+$945M |
| 2 |
Microsoft
MSFT
|
+$881M |
| 3 |
Amazon
AMZN
|
+$613M |
| 4 |
Tesla
TSLA
|
+$540M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$502M |
Top Sells
| 1 |
Abbott
ABT
|
+$959M |
| 2 |
Linde
LIN
|
+$929M |
| 3 |
Exxon Mobil
XOM
|
+$336M |
| 4 |
VMW
VMware, Inc
VMW
|
+$225M |
| 5 |
NVIDIA
NVDA
|
+$199M |
Sector Composition
| 1 | Technology | 30.4% |
| 2 | Healthcare | 13.37% |
| 3 | Consumer Discretionary | 11.23% |
| 4 | Financials | 10.99% |
| 5 | Communication Services | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2501
ICL Group
ICL
$7.87B
| $107K | ﹤0.01% |
+19,289
| New | +$107K |
|
2502
Clarus
CLAR
$154M
| $104K | ﹤0.01% |
13,754
| – | – |
|
2503
SoundHound AI
SOUN
$6.05B
| $98.7K | ﹤0.01% |
+49,100
| New | +$98.7K |
|
2504
SES AI
SES
$413M
| $98.1K | ﹤0.01% |
43,234
| – | – |
|
2505
Origin Materials
ORGN
$78.5M
| $93.7K | ﹤0.01% |
73,191
| – | – |
|
2506
ATAI Life Sciences
ATAI
$1.05B
| $93.5K | ﹤0.01% |
72,480
+9,269
| +15% | +$12K |
|
|
IGMS
2507
DELISTED
IGM Biosciences
IGMS
| $93.1K | ﹤0.01% |
11,145
-473,882
| -98% | -$3.96M |
|
2508
Vivid Seats
SEAT
$102M
| $91.1K | ﹤0.01% |
+709
| New | +$91.1K |
|
2509
NerdWallet
NRDS
$825M
| $88.9K | ﹤0.01% |
+10,000
| New | +$88.9K |
|
2510
Imperial Oil
IMO
$45.6B
| $82.5K | ﹤0.01% |
+1,339
| New | +$82.5K |
|
|
VZIO
2511
DELISTED
VIZIO Holding Corp.
VZIO
| $77.4K | ﹤0.01% |
+14,300
| New | +$77.4K |
|
2512
Fate Therapeutics
FATE
$113M
| $75.1K | ﹤0.01% |
35,408
| – | – |
|
2513
Aldeyra Therapeutics
ALDX
$346M
| $74.9K | ﹤0.01% |
+11,212
| New | +$74.9K |
|
2514
Advantage Solutions
ADV
$623M
| $71.7K | ﹤0.01% |
25,234
-21,500
| -46% | -$61.1K |
|
|
NUTX
2515
Nutex Health
NUTX
$477M
| $66K | ﹤0.01% |
2,173
| – | – |
|
2516
Axogen
AXGN
$756M
| $52.7K | ﹤0.01% |
+10,538
| New | +$52.7K |
|
|
KLRS
2517
Kalaris Therapeutics, Inc. Common Stock
KLRS
$87.5M
| $50.9K | ﹤0.01% |
1,029
| – | – |
|
|
CANO
2518
DELISTED
Cano Health, Inc.
CANO
| $50.1K | ﹤0.01% |
1,977
| – | – |
|
2519
ARS Pharmaceuticals
SPRY
$1.02B
| $48.9K | ﹤0.01% |
+12,940
| New | +$48.9K |
|
2520
Lyell Immunopharma
LYEL
$253M
| $48.5K | ﹤0.01% |
+1,650
| New | +$48.5K |
|
2521
Stoke Therapeutics
STOK
$1.21B
| $44.9K | ﹤0.01% |
11,398
| – | – |
|
|
API
2522
Agora
API
$328M
| $43.8K | ﹤0.01% |
17,300
| – | – |
|
2523
TeraWulf
WULF
$4.04B
| $40.8K | ﹤0.01% |
+32,400
| New | +$40.8K |
|
|
RAD
2524
DELISTED
Rite Aid Corporation
RAD
| $13.6K | ﹤0.01% |
30,345
-23,715
| -44% | -$10.6K |
|
|
DOYU
2525
DouYu International Holdings
DOYU
$241M
| $10.4K | ﹤0.01% |
1,067
| – | – |
|